Enter drug's generic or brand name below. Results will appear here. Note: all drug related information obtained on this page is provided by RX List.
Using the RX LIST database:
(1) Enter the drug name in the search box below and hit ENTER
(2) The rx list web site will open here with the drug search completed. Next, scroll down the page to locate the link to the drug you are searching for and then click on the link.
What is Ultomiris?
Ultomiris is a prescription medicine called a monoclonal antibody. Ultomiris is used to treat:
It is not known if Ultomiris is safe and effective in children with PNH.
It is not known if Ultomiris is safe and effective in children younger than 1 month of age.
What are the possible side effects of Ultomiris?
Ultomiris can cause serious side effects including:
Your doctor will treat your symptoms as needed.
The most common side effects of Ultomiris in people treated for PNH are upper respiratory infection and headache.
The most common side effects of Ultomiris in people with aHUS are:
Tell your doctor about any side effect that bothers you or that does not go away.
These are not all the possible side effects of Ultomiris. For more information, ask your doctor or pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
WARNING
SERIOUS MENINGOCOCCAL INFECTIONS
ULTOMIRIS is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS). Under the ULTOMIRIS REMS, prescribers must enroll in the program [see WARNINGS AND PRECAUTIONS]. Enrollment in the ULTOMIRIS REMS program and additional information are available by telephone: 1-844-259-6783 or at www.ultomirisrems.com.
Ravulizumab-cwvz, a complement inhibitor, is a humanized monoclonal antibody (mAb) produced in Chinese hamster ovary (CHO) cells. Ravulizumab-cwvz consists of 2 identical 448 amino acid heavy chains and 2 identical 214 amino acid light chains and has a molecular weight of approximately 148 kDa. The constant regions of ravulizumabcwvz include the human kappa light chain constant region, and the protein engineered “IgG2/4” heavy chain constant region.
The heavy chain CH1 domain, hinge region, and the first 5 amino acids of the CH2 domain match the human IgG2 amino acid sequence, residues 6 to 36 in the CH2 region (common to both human IgG2 and IgG4 amino acid sequences), while the remainder of the CH2 domain and the CH3 domain match the human IgG4 amino acid sequence. The heavy and light chain variable regions that form the human C5 binding site consist of human framework regions grafted to murine complementarity-determining regions.
ULTOMIRIS (ravulizumab-cwvz) injection is a sterile, clear to translucent, slight whitish color, preservative-free solution for intravenous use. Each single-dose vial contains 300 mg ravulizumab-cwvz at a concentration of 10 mg/mL with a pH of 7.0. Each mL also contains polysorbate 80 (0.2 mg) (vegetable origin), sodium chloride (8.77 mg), sodium phosphate dibasic (1.78 mg), sodium phosphate monobasic (0.46 mg), and Water for Injection, USP.
ULTOMIRIS is indicated for:
ULTOMIRIS is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS).
Vaccinate patients for meningococcal disease according to current ACIP guidelines to reduce the risk of serious infection [see WARNINGS AND PRECAUTIONS].
Provide 2 weeks of antibacterial drug prophylaxis to patients if ULTOMIRIS must be initiated immediately and vaccines are administered less than 2 weeks before starting ULTOMIRIS therapy.
Healthcare professionals who prescribe ULTOMIRIS must enroll in the ULTOMIRIS REMS [see WARNINGS AND PRECAUTIONS].
The recommended dosing regimen in adult patients with PNH weighing 40 kg or greater, consists of a loading dose followed by maintenance dosing, administered by intravenous infusion. Administer the doses based on the patient’s body weight, as shown in Table 1. Starting 2 weeks after the loading dose administration, begin maintenance doses at a once every 8-week interval.
The dosing schedule is allowed to occasionally vary within 7 days of the scheduled infusion day (except for the first maintenance dose of ULTOMIRIS); but the subsequent doses should be administered according to the original schedule.
Table 1: ULTOMIRIS Weight-Based Dosing Regimen – PNH
| Body Weight Range (kg) | Loading Dose (mg) | Maintenance Dose (mg) and Dosing Interval | |
| greater than or equal to 40 to less than 60 | 2,400 | 3,000 | Every 8 weeks |
| greater than or equal to 60 to less than 100 | 2,700 | 3,300 | |
| greater than or equal to 100 | 3,000 | 3,600 | |
The recommended dosing regimen in adult and pediatric patients one month of age and older with aHUS weighing 5 kg or greater, consists of a loading dose followed by maintenance dosing, administered by intravenous infusion. Administer the doses based on the patient’s body weight, as shown in Table 2. Starting 2 weeks after the loading dose administration, begin maintenance doses once every 8 weeks or every 4 weeks (depending on body weight).
The dosing schedule is allowed to occasionally vary within 7 days of the scheduled infusion day (except for the first maintenance dose of ULTOMIRIS); but the subsequent doses should be administered according to the original schedule.
Table 2: ULTOMIRIS Weight-Based Dosing Regimen – aHUS
| Body Weight Range (kg) | Loading Dose (mg) | Maintenance Dose (mg) and Dosing Interval | |
| greater than or equal to 5 to less than 10 | 600 | 300 | Every 4 weeks |
| greater than or equal to 10 to less than 20 | 600 | 600 | |
| greater than or equal to 20 to less than 30 | 900 | 2,100 | Every 8 weeks |
| greater than or equal to 30 to less than 40 | 1,200 | 2,700 | |
| greater than or equal to 40 to less than 60 | 2,400 | 3,000 | |
| greater than or equal to 60 to less than 100 | 2,700 | 3,300 | |
| greater than or equal to 100 | 3,000 | 3,600 | |
For patients switching from eculizumab to ULTOMIRIS, administer the loading dose of ULTOMIRIS 2 weeks after the last eculizumab infusion, and then administer maintenance doses once every 8 weeks or every 4 weeks (depending on body weight), starting 2 weeks after loading dose administration.
Administration of PE/PI (plasmapheresis or plasma exchange, or fresh frozen plasma infusion) may reduce ULTOMIRIS serum levels. There is no experience with administration of supplemental doses of ULTOMIRIS.
Each vial of ULTOMIRIS is intended for single-dose only.
ULTOMIRIS requires dilution to a final concentration of 5 mg/mL.
Use aseptic technique to prepare ULTOMIRIS as follows:
Only administer as an intravenous infusion.
Dilute ULTOMIRIS to a final concentration of 5 mg/mL.
Administer ULTOMIRIS only through a 0.2 or 0.22 micron filter.
Table 3: Loading Dose Administration Reference Table
| Body Weight Range (kg)a | Loading Dose (mg) | ULTOMIRIS Volume (mL) | Volume of NaCl Diluentb (mL) | Total Volume (mL) | Minimum Infusion Time (hr) | Maximum Infusion Rate (mL/hr) |
| greater than or equal to 5 to less than 10 | 600 | 60 | 60 | 120 | 3.8 | 31 |
| greater than or equal to 10 to less than 20 | 600 | 60 | 60 | 120 | 1.9 | 63 |
| greater than or equal to 20 to less than 30 | 900 | 90 | 90 | 180 | 1.5 | 120 |
| greater than or equal to 30 to less than 40 | 1,200 | 120 | 120 | 240 | 1.3 | 184 |
| greater than or equal to 40 to less than 60 | 2,400 | 240 | 240 | 480 | 1.9 | 252 |
| greater than or equal to 60 to less than 100 | 2,700 | 270 | 270 | 540 | 1.7 | 317 |
| greater than or equal to 100 | 3,000 | 300 | 300 | 600 | 1.8 | 333 |
| a Body weight at time of treatment. b Dilute ULTOMIRIS only using 0.9% Sodium Chloride Injection, USP. |
||||||
Table 4: Maintenance Dose
Administration Reference Table
| Body Weight Range (kg)a | Maintenance Dose (mg) | ULTOMIRIS Volume (mL) | Volume of NaCl Diluentb(mL) | Total Volume (mL) | Minimum Infusion Time (hr) | Maximum Infusion Rate (mL/hr) |
| greater than or equal to 5 to less than 10 | 300 | 30 | 30 | 60 | 1.9 | 31 |
| greater than or equal to 10 to less than 20 | 600 | 60 | 60 | 120 | 1.9 | 63 |
| greater than or equal to 20 to less than 30 | 2,100 | 210 | 210 | 420 | 3.3 | 127 |
| greater than or equal to 30 to less than 40 | 2,700 | 270 | 270 | 540 | 2.8 | 192 |
| greater than or equal to 40 to less than 60 | 3,000 | 300 | 300 | 600 | 2.3 | 257 |
| greater than or equal to 60 to less than 100 | 3,300 | 330 | 330 | 660 | 2 | 330 |
| greater than or equal to 100 | 3,600 | 360 | 360 | 720 | 2.2 | 327 |
| a Body weight at time of treatment. b Dilute ULTOMIRIS only using 0.9% Sodium Chloride Injection, USP. |
||||||
Prior to administration, allow the admixture to adjust to room temperature (18°C-25°C, 64°F-77°F). Do not heat the admixture in a microwave or with any heat source other than ambient air temperature.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
If an adverse reaction occurs during the administration of ULTOMIRIS, the infusion may be slowed or stopped at the discretion of the physician. Monitor the patient for at least one hour following completion of the infusion for signs or symptoms of an infusion reaction.
Injection: 300 mg/30 mL (10 mg/mL) as a clear to translucent, slight whitish color solution in a single-dose vial.
ULTOMIRIS (ravulizumab-cwvz) injection is a clear to translucent, slight whitish color preservative-free, solution supplied as one 300 mg/30 mL (10 mg/mL) single-dose vial per carton. NDC 25682-022-01.
Store ULTOMIRIS vials refrigerated at 2°C - 8°C (36°F - 46°F) in the original carton to protect from light. Do not freeze. Do not shake.
Refer to Dosage and Administration for information on the stability and storage of diluted solutions of ULTOMIRIS.
Manufactured by: Alexion Pharmaceuticals, Inc. 121 Seaport Boulevard Boston, MA 02210 USA. Revised: Oct 2019
The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling:
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The data described below reflect exposure of 441 adult patients with PNH in Phase 3 studies who received ULTOMIRIS (n = 222) or eculizumab (n = 219) at the recommended dosing regimens with median treatment duration of 6 months for ULTOMIRIS and 6 months for eculizumab. The most frequent adverse reactions (≥10%) with ULTOMIRIS were upper respiratory tract infection and headache. Table 5 describes adverse reactions that occurred at a rate of 5% or more among patients treated with ULTOMIRIS in PNH studies.
Serious adverse reactions were reported in 15 (6.8%) patients with PNH receiving ULTOMIRIS. The serious adverse reactions in patients treated with ULTOMIRIS included hyperthermia and pyrexia. No serious adverse reaction was reported in more than 1 patient treated with ULTOMIRIS.
One fatal case of sepsis was identified in a patient treated with ULTOMIRIS.
Table 5: Adverse Reactions Reported in 5% or More of
ULTOMIRIS-Treated Patients in Complement Inhibitor Naive and
Eculizumab-Experienced Patients with PNH
| Body System Adverse Reaction |
Number of Patients | |
| ULTOMIRIS (N=222) n (%) |
Eculizumab (N=219) n (%) |
|
| Gastrointestinal disorders | ||
| Diarrhea | 19 (9) | 12 (5) |
| Nausea | 19 (9) | 19 (9) |
| Abdominal pain | 13 (6) | 16 (7) |
| General Disorders and Administration Site Conditions | ||
| Pyrexia | 15 (7) | 18 (8) |
| Infections and Infestations | ||
| Upper respiratory tract infectiona | 86 (39) | 86 (39) |
| Musculoskeletal and Connective Tissue Disorders | ||
| Pain in extremity | 14 (6) | 11 (5) |
| Arthralgia | 11 (5) | 12 (5) |
| Nervous System Disorders | ||
| Headache | 71 (32) | 57 (26) |
| Dizziness | 12 (5) | 14 (6) |
| a Grouped term includes: Nasopharyngitis, Upper respiratory tract infection, Oropharyngeal pain, Viral upper respiratory tract infection, Rhinitis, Respiratory tract infection, Rhinorrhea, Pharyngitis, and Upper respiratory tract inflammation | ||
The data described below reflect exposure of 58 adult and 16 pediatric patients with aHUS in single-arm trials who received ULTOMIRIS at the recommended dose and schedule. The most frequent adverse reactions reported in ≥20% of patients treated with ULTOMIRIS were upper respiratory tract infection, diarrhea, nausea, vomiting, headache, hypertension and pyrexia. Tables 6, 7 and 8 describes adverse reactions that occurred at a rate of 10% or more among patients treated with ULTOMIRIS in aHUS studies. Serious adverse reactions were reported in 42 (57%) patients with aHUS receiving ULTOMIRIS. The most frequent serious adverse reactions reported in more than 2 patients (2.7%) treated with ULTOMIRIS were hypertension, pneumonia and abdominal pain. Four patients died during the ALXN1210-aHUS-311 study. The cause of death was sepsis in two patients and intracranial hemorrhage in one patient. The fourth patient, who was excluded from the trial after a diagnosis of STEC-HUS, died due to pretreatment cerebral arterial thrombosis.
Table 6: Adverse Reactions Reported in ≥10% of
ULTOMIRIS-Treated Patients with aHUS in Study ALXN1210-aHUS-311
| Body System Adverse Reaction |
ALXN1210-aHUS-311 (N=58) |
|
| All Grades*** (n=53) n (%) |
≥ Grade 3 (n=14) n (%) |
|
| Blood and lymphatic system disorders | ||
| Anemia | 8 (14) | 0 (0) |
| Gastrointestinal disorders | ||
| Diarrhea | 18 (31) | 2 (3) |
| Nausea | 15 (26) | 2 (3) |
| Vomiting | 15 (26) | 2 (3) |
| Constipation | 8 (14) | 1 (2) |
| Abdominal pain | 7 (12) | 1 (2) |
| General disorders and administration site conditions | ||
| Pyrexia | 11 (19) | 1 (2) |
| Edema peripheral | 10 (17) | 0 (0) |
| Fatigue | 8 (14) | 0 (0) |
| Infections and infestations | ||
| Upper respiratory tract infection* | 15 (26) | 0 (0) |
| Urinary tract infection | 10 (17) | 5 (9) |
| Gastrointestinal infection** | 8 (14) | 2 (3) |
| Metabolism and nutrition disorders | ||
| Hypokalemia | 6 (10) | 1 (2) |
| Musculoskeletal and connective tissue disorders | ||
| Arthralgia | 13 (22) | 0 (0) |
| Back pain | 7 (12) | 1 (2) |
| Muscle spasms | 6 (10) | 0 (0) |
| Pain in extremity | 6 (10) | 0 (0) |
| Nervous system disorders | ||
| Headache | 23 (40) | 1 (2) |
| Psychiatric disorders | ||
| Anxiety | 8 (14) | 1 (2) |
| Respiratory, thoracic and mediastinal disorders | ||
| Cough | 10 (17) | 0 (0) |
| Dyspnea | 10 (17) | 1 (2) |
| Skin and subcutaneous tissue disorders | ||
| Alopecia | 6 (10) | 0 (0) |
| Dry skin | 6 (10) | 0 (0) |
| Vascular disorders | ||
| Hypertension | 14 (24) | 7 (12) |
| *: Grouped term includes
Nasopharyngitis, Pharyngitis, Upper respiratory tract infection, Rhinitis,
Viral upper respiratory tract infection, Rhinovirus infection, Viral
pharyngitis, Rhinorrhea, and Oropharyngeal pain. **: Grouped term includes Gastroenteritis, Gastrointestinal infection, Enterocolitis infectious, Infectious colitis, and Enterocolitis. ***: Graded per CTCAE v5.0. |
||
Clinically relevant adverse reactions in <10% of patients include viral tonsillitis.
Table 7: Adverse Reactions Reported in ≥10% of
ULTOMIRIS-Treated Patients with aHUS in Study ALXN1210-aHUS-312
| Body System Adverse Reaction |
ALXN1210-aHUS-312 (N=16) |
|
| All Grades** (n=16) n (%) |
≥ Grade 3 (n=6) n (%) |
|
| Blood and lymphatic system disorders | ||
| Anemia | 2 (13) | 1 (6) |
| Lymphadenopathy | 2 (13) | 0 (0) |
| Gastrointestinal disorders | ||
| Diarrhea | 6 (38) | 0 (0) |
| Constipation | 4 (25) | 0 (0) |
| Vomiting | 4 (25) | 1 (6) |
| Abdominal pain | 3 (19) | 0 (0) |
| Nausea | 2 (13) | 0 (0) |
| General disorders and administration site conditions | ||
| Pyrexia | 8 (50) | 0 (0) |
| Infections and infestations | ||
| Upper respiratory tract infection* | 7 (44) | 1 (6) |
| Gastroenteritis viral | 2 (13) | 2 (13) |
| Pneumonia | 2 (13) | 1 (6) |
| Tonsillitis | 2 (13) | 0 (0) |
| Injury, poisoning and procedural complications | ||
| Contusion | 3 (19) | 0 (0) |
| Investigations | ||
| Vitamin D decreased | 3 (19) | 0 (0) |
| Metabolism and nutrition disorders | ||
| Decreased appetite | 2 (13) | 0 (0) |
| Iron deficiency | 2 (13) | 0 (0) |
| Musculoskeletal and connective tissue disorders | ||
| Myalgia | 3 (19) | 0 (0) |
| Pain in extremity | 2 (13) | 0 (0) |
| Nervous system disorders | ||
| Headache | 5 (31) | 0 (0) |
| Respiratory, thoracic and mediastinal disorders | ||
| Cough | 3 (19) | 0 (0) |
| Dyspnea | 2 (13) | 0 (0) |
| Skin and subcutaneous tissue disorders | ||
| Rash | 3 (19) | 0 (0) |
| Vascular disorders | ||
| Hypertension | 4 (25) | 1 (6) |
| Hypotension | 2 (13) | 0 (0) |
| *: Grouped term includes
Nasopharyngitis, Pharyngitis, Upper respiratory tract infection, Rhinitis,
Viral upper respiratory tract infection, Rhinovirus infection, Viral
pharyngitis, Rhinorrhea, and Oropharyngeal pain. **:Graded per CTCAE v5.0. |
||
Clinically relevant adverse reactions in <10% of patients include viral infection.
Table 8: Adverse Reactions Reported in ≥10% of
ULTOMIRIS Treated Patients from Birth to 16 Years of Age with aHUS in Study
ALXN1210-aHUS-312
| Body System Adverse Reaction |
ALXN1210-aHUS-312 | |||
| Age 0 to <2 (N=2) |
Age 2 to <12 (N=12) |
Age 12 to 16 (N=1) |
Total (N=15) |
|
| n (%) | n (%) | n (%) | n (%) | |
| Blood and lymphatic system disorders | ||||
| Lymphadenopathy | 0 (0) | 2 (17) | 0 (0) | 2 (13) |
| Gastrointestinal disorders | ||||
| Diarrhea | 1 (50) | 3 (25) | 1 (100) | 5 (33) |
| Constipation | 0 (0) | 4 (33) | 0 (0) | 4 (27) |
| Vomiting | 0 (0) | 3 (25) | 0 (0) | 3 (20) |
| Abdominal pain | 0 (0) | 2 (17) | 0 (0) | 2 (13) |
| General disorders and administration site conditions | ||||
| Pyrexia | 1 (50) | 5 (42) | 1 (100) | 7 (47) |
| Infections and infestations | ||||
| Upper respiratory tract infection* | 1 (50) | 6 (50) | 0 (0) | 7 (47) |
| Gastroenteritis viral | 0 (0) | 2 (17) | 0 (0) | 2 (13) |
| Tonsillitis | 1 (50) | 1 (8) | 0 (0) | 2 (13) |
| Injury, poisoning and procedural complications | ||||
| Contusion | 0 (0) | 2 (17) | 0 (0) | 2 (13) |
| Investigations | ||||
| Vitamin D decreased | 0 (0) | 2 (17) | 1 (100) | 3 (20) |
| Metabolism and nutrition disorders | ||||
| Decreased appetite | 1 (50) | 1 (8) | 0 (0) | 2 (13) |
| Iron deficiency | 0 (0) | 2 (17) | 0 (0) | 2 (13) |
| Musculoskeletal and connective tissue disorders | ||||
| Myalgia | 1 (50) | 1 (8) | 0 (0) | 2 (13) |
| Pain in extremity | 0 (0) | 2 (17) | 0 (0) | 2 (13) |
| Nervous system disorders | ||||
| Headache | 0 (0) | 4 (33) | 0 (0) | 4 (27) |
| Respiratory, thoracic and mediastinal disorders | ||||
| Cough | 0 (0) | 3 (25) | 0 (0) | 3 (20) |
| Dyspnea | 1 (50) | 1 (8) | 0 (0) | 2 (13) |
| Skin and subcutaneous tissue disorders | ||||
| Rash | 1 (50) | 2 (17) | 0 (0) | 3 (20) |
| Vascular disorders | ||||
| Hypertension | 1 (50) | 3 (25) | 0 (0) | 4 (27) |
| Hypotension | 0 (0) | 2 (17) | 0 (0) | 2 (13) |
| *: Grouped term includes Nasopharyngitis, Pharyngitis, Upper respiratory tract infection, Rhinitis, Viral upper respiratory tract infection, Rhinovirus infection, Viral pharyngitis, Rhinorrhea, and Oropharyngeal pain | ||||
Clinically relevant adverse reactions in <10% of patients include viral infection.
As with all therapeutic proteins, there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibodies) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications and underlying disease. For these reasons, comparison of the incidence of antibodies in the studies described below with the incidence of antibodies in other studies or to other ravulizumab products may be misleading.
The immunogenicity of ravulizumab-cwvz has been evaluated using an enzyme-linked immunosorbent assay (ELISA) for the detection of binding anti-ravulizumab-cwvz antibodies. For patients whose sera tested positive in the screening immunoassay, an in vitro biological assay was performed to detect neutralizing antibodies.
In clinical studies, treatment-emergent antibodies to ravulizumab-cwvz were detected in 1 of 206 (0.5%) patients with PNH and 1 of 71 (1.4%) patients with aHUS. No apparent correlation of antibody development to altered pharmacokinetic profile, clinical response, or adverse events was observed.
No Information provided
Included as part of the PRECAUTIONS section.
Life-threatening meningococcal infections have occurred in patients treated with ULTOMIRIS. The use of ULTOMIRIS increases a patient’s susceptibility to serious meningococcal infections (septicemia and/or meningitis). Meningococcal disease due to any serogroup may occur.
Vaccinate for meningococcal disease according to the most current Advisory Committee on Immunization Practices (ACIP) recommendations for patients with complement deficiencies. Revaccinate patients in accordance with ACIP recommendations considering the duration of ULTOMIRIS therapy.
Immunize patients without a history of meningococcal vaccination at least 2 weeks prior to receiving the first dose of ULTOMIRIS. If urgent ULTOMIRIS therapy is indicated in an unvaccinated patient, administer meningococcal vaccine(s) as soon as possible and provide patients with 2 weeks of antibacterial drug prophylaxis.
In clinical studies, 59 patients with PNH were treated with ULTOMIRIS less than 2 weeks after meningococcal vaccination. All of these patients received antibiotics for prophylaxis of meningococcal infection until at least 2 weeks after meningococcal vaccination. The benefits and risks of antibiotic prophylaxis for prevention of meningococcal infections in patients receiving ULTOMIRIS have not been established.
Vaccination reduces, but does not eliminate, the risk of meningococcal infections. In PNH clinical studies, 3 out of 261 PNH patients developed serious meningococcal infections/sepsis while receiving treatment with ULTOMIRIS; all 3 had been vaccinated. These 3 patients recovered while continuing treatment with ULTOMIRIS.
Closely monitor patients for early signs and symptoms of meningococcal infection and evaluate patients immediately if infection is suspected. Inform patients of these signs and symptoms and steps to be taken to seek immediate medical care. Meningococcal infection may become rapidly life-threatening or fatal if not recognized and treated early. Consider discontinuation of ULTOMIRIS in patients who are undergoing treatment for serious meningococcal infection.
Due to the risk of meningococcal infections, ULTOMIRIS is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS). Under the ULTOMIRIS REMS, prescribers must enroll in the program.
Prescribers must counsel patients about the risk of meningococcal infection/sepsis, provide the patients with the REMS educational materials, and ensure patients are vaccinated with meningococcal vaccines.
Enrollment in the ULTOMIRIS REMS and additional information are available by telephone: 1-888-765-4747 or at www.ultomirisrems.com.
ULTOMIRIS blocks terminal complement activation; therefore, patients may have increased susceptibility to encapsulated bacteria infections, especially infections caused by Neisseria meningitidis but also Streptococcus pneumoniae, Haemophilus influenzae, and to a lesser extent, Neisseria gonorrhoeae. Children treated with ULTOMIRIS may be at increased risk of developing serious infections due to Streptococcus pneumoniae and Haemophilus influenzae type b (Hib). Administer vaccinations for the prevention of Streptococcus pneumoniae and Haemophilus influenzae type b (Hib) infections according to ACIP guidelines. If ULTOMIRIS therapy is administered to patients with active systemic infections, monitor closely for signs and symptoms of worsening infection.
After discontinuing treatment with ULTOMIRIS, closely monitor for signs and symptoms of hemolysis, identified by elevated LDH along with sudden decrease in PNH clone size or hemoglobin, or re-appearance of symptoms such as fatigue, hemoglobinuria, abdominal pain, shortness of breath (dyspnea), major adverse vascular event (including thrombosis), dysphagia, or erectile dysfunction. Monitor any patient who discontinues ULTOMIRIS for at least 16 weeks to detect hemolysis and other reactions. If signs and symptoms of hemolysis occur after discontinuation, including elevated LDH, consider restarting treatment with ULTOMIRIS.
ULTOMIRIS treatment of aHUS should be a minimum duration of 6 months. Due to heterogeneous nature of aHUS events and patient-specific risk factors, treatment duration beyond the initial 6 months should be individualized.
There are no specific data on ULTOMIRIS discontinuation.
After discontinuing treatment with ULTOMIRIS, patients should be monitored for clinical symptoms and laboratory signs of TMA complications for at least 12 months.
TMA complications post-discontinuation can be identified if any of the following is observed:
If TMA complications occur after ULTOMIRIS discontinuation, consider reinitiation of ULTOMIRIS treatment or appropriate organ-specific supportive measures.
The effect of withdrawal of anticoagulant therapy during ULTOMIRIS treatment has not been established. Therefore, treatment with ULTOMIRIS should not alter anticoagulant management.
Administration of ULTOMIRIS may result in infusion reactions. In clinical trials, 5 out of 296 patients treated with ULTOMIRIS experienced infusion reactions (lower back pain, drop in blood pressure, infusion-related pain, elevation in blood pressure and limb discomfort) during ULTOMIRIS administration. These reactions did not require discontinuation of ULTOMIRIS. Interrupt ULTOMIRIS infusion and institute appropriate supportive measures if signs of cardiovascular instability or respiratory compromise occur.
Advise the patient to read FDA-approved patient labeling (Medication Guide).
Advise patients of the risk of meningococcal infection/sepsis. Inform patients that they are required to receive meningococcal vaccination at least 2 weeks prior to receiving the first dose of ULTOMIRIS, if they have not previously been vaccinated. They are required to be revaccinated according to current medical guidelines for meningococcal vaccines use while on ULTOMIRIS therapy. Inform patients that vaccination may not prevent meningococcal infection. Inform patients about the signs and symptoms of meningococcal infection/sepsis, and strongly advise patients to seek immediate medical attention if these signs or symptoms occur. These signs and symptoms are as follows:
Inform patients that they will be given an ULTOMIRIS Patient Safety Card that they should carry with them at all times. This card describes symptoms which, if experienced, should prompt the patient to immediately seek medical evaluation.
Counsel patients of the increased risk of infections, particularly those due to encapsulated bacteria, especially Neisseria species. Advise patients of the need for vaccination against meningococcal infections according to current medical guidelines. Counsel patients about gonorrhea prevention and advise regular testing for patients at risk. Advise patients to report any new signs and symptoms of infection.
Inform patients with PNH or aHUS that they may develop hemolysis or TMA, respectively, when ULTOMIRIS is discontinued and that they will be monitored by their healthcare professional for at least 16 weeks for PNH or at least 12 months for aHUS following ULTOMIRIS discontinuation.
Inform patients who discontinue ULTOMIRIS to keep the ULTOMIRIS Patient Safety Card with them for eight months after the last ULTOMIRIS dose, because the increased risk of meningococcal infection persists for several weeks following discontinuation of ULTOMIRIS.
Advise patients that administration of ULTOMIRIS may result in infusion reactions.
Long-term animal carcinogenicity studies of ravulizumab-cwvz have not been conducted.
Genotoxicity studies have not been conducted with ravulizumab-cwvz.
Effects of ravulizumab-cwvz upon fertility have not been studied in animals. Intravenous injections of male and female mice with a murine anti-C5 antibody at up to 0.8-2.2 times the equivalent of the clinical dose of ULTOMIRIS had no adverse effects on mating or fertility.
There are no available data on ULTOMIRIS use in pregnant women to inform a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. There are risks to the mother and fetus associated with untreated PNH and aHUS in pregnancy (see Clinical Considerations). Animal studies using a mouse analogue of the ravulizumab-cwvz molecule (murine anti-C5 antibody) showed increased rates of developmental abnormalities and an increased rate of dead and moribund offspring at doses 0.8-2.2 times the human dose (see Data).
The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.
Disease-Associated Maternal And/Or Fetal/Neonatal Risk
PNH in pregnancy is associated with adverse maternal outcomes, including worsening cytopenias, thrombotic events, infections, bleeding, miscarriages, and increased maternal mortality, and adverse fetal outcomes, including fetal death and premature delivery.
In pregnancy, aHUS is associated with adverse maternal outcomes, including preeclampsia and preterm delivery, and adverse fetal/neonatal outcomes, including intrauterine growth restriction (IUGR), fetal death and low birth weight.
Animal Data
Animal reproduction studies were conducted in mice using doses of a murine anti-C5 antibody that approximated 1-2.2 times (loading dose) and 0.8-1.8 times (maintenance dose) the recommended human ULTOMIRIS dose, based on a body weight comparison. When animal exposure to the antibody occurred in the time period from before mating until early gestation, no decrease in fertility or reproductive performance was observed. When maternal exposure to the antibody occurred during organogenesis, two cases of retinal dysplasia and one case of umbilical hernia were observed among 230 offspring born to mothers exposed to the higher antibody dose; however, the exposure did not increase fetal loss or neonatal death. When maternal exposure to the antibody occurred in the time period from implantation through weaning, a higher number of male offspring became moribund or died (1/25 controls, 2/25 low dose group, 5/25 high dose group). Surviving offspring had normal development and reproductive function. Human IgG are known to cross the human placental barrier, and thus ULTOMIRIS may potentially cause terminal complement inhibition in the fetal circulation.
There are no data on the presence of ravulizumab-cwvz in human milk, the effect on the breastfed child, or the effect on milk production. Since many medicinal products and immunoglobulins are secreted into human milk, and because of the potential for serious adverse reactions in a nursing child, breastfeeding should be discontinued during treatment and for 8 months after the final dose.
The safety and efficacy of ULTOMIRIS for the treatment of PNH in pediatric patients have not been established.
The safety and effectiveness of ULTOMIRIS for the treatment of aHUS have been established in pediatric patients aged one month and older. Use of ULTOMIRIS for this indication is supported by evidence from adequate and well-controlled studies in adults with additional pharmacokinetic, safety, and efficacy data in pediatric patients aged 10 months to <17 years. The safety and efficacy of ULTOMIRIS for the treatment of aHUS appear similar in pediatric and adult patients [see ADVERSE REACTIONS, and Clinical Studies].
Clinical studies of ULTOMIRIS did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.
No Information provided
ULTOMIRIS is contraindicated in:
Ravulizumab-cwvz is a terminal complement inhibitor that specifically binds to the complement protein C5 with high affinity, thereby inhibiting its cleavage to C5a (the proinflammatory anaphylatoxin) and C5b (the initiating subunit of the terminal complement complex [C5b-9]) and preventing the generation of the terminal complement complex C5b9. ULTOMIRIS inhibits terminal complement-mediated intravascular hemolysis in patients with PNH and complement-mediated thrombotic microangiopathy (TMA) in patients with aHUS.
Complete inhibition of serum free C5 (concentration of less than 0.5 mcg/mL) was observed by the end of the first ULTOMIRIS infusion and sustained throughout the entire 26-week treatment period in all adult patients with PNH and in the majority (93%) of adult and pediatric patients with aHUS.
The extent and duration of the pharmacodynamic response in patients with PNH and aHUS were exposure-dependent for ULTOMIRIS. Free C5 levels of <0.5 mcg/mL were correlated with maximal intravascular hemolysis control and complete terminal complement inhibition in patients with PNH.
Complete terminal complement inhibition following initiation of ULTOMIRIS treatment led to normalization of serum LDH by week 4 in complement-inhibitor naive patients with PNH, and maintained LDH normalization in patients previously treated with eculizumab with PNH [see Clinical Studies].
Ravulizumab-cwvz pharmacokinetics increase proportionally over a dose range of 200 to 5400 mg. Ravulizumab-cwvz Cmax and Ctrough parameters are presented in Table 9 and Table 10.
Table 9: Mean (%CV) Pharmacokinetic Parameters of
ULTOMIRIS in Patients with PNH who are Complement Inhibitor-Naive and Patients Previously
Treated with Eculizumab
| N | Complement Inhibitor-Naive (ALXN1210-PNH-301) | N | Previously Treated with Eculizumab (ALXN1210-PNH-302) | ||
| Cmax (mcg/mL) | LD | 125 | 771 (21.5) | 95 | 843 (24.1) |
| MD | 124 | 1,379 (20.0) | 95 | 1,386 (19.4) | |
| Ctrough (mcg/mL) | LD | 125 | 391 (35.0) | 96 | 405 (29.9) |
| MD | 124 | 473 (33.4) | 95 | 501 (28.6) | |
| LD = Loading Dose; MD = Maintenance Dose | |||||
Table 10: Mean (%CV) Pharmacokinetic Parameters of
ULTOMIRIS in Patients with aHUS
| Pediatric Patients (ALXN1210-aHUS-312) | Adult Patients (ALXN1210-aHUS-311) | ||||||
| N | < 20 kg MD Q4W | N | ≥ 20 to < 40 kg MD Q8W | N | ≥ 40 kg MD Q8W | ||
| Cmax (mcg/mL) | LD | 8 | 656 (38.1) | 4 | 600 (17.3) | 52 | 754 (35.2) |
| MD | 7 | 1,467 (37.8) | 6 | 1,863 (15.3) | 46 | 1,458 (17.6) | |
| Ctrough (mcg/mL) | LD | 9 | 241 (52.1) | 5 | 186 (16.5) | 55 | 313 (33.9) |
| MD | 7 | 683 (46.1) | 6 | 549 (34.1) | 46 | 507 (42.5) | |
| LD = Loading Dose; MD = Maintenance Dose; Q4W = Every 4 Weeks; Q8W = Every 8 Weeks | |||||||
The mean (%CV) volume of distribution at steady state was 5.34 (17.2) L and 5.22 (35.4) L in patients with PNH and aHUS, respectively.
The mean (%CV) terminal elimination half-life of ravulizumab-cwvz in patients with PNH and aHUS are 49.7 (18.0) days and 51.8 (31.3) days, respectively. The mean (%CV) clearance of ravulizumab-cwvz in patients with PNH and aHUS are 0.08 (29.5) L/day and 0.08 (53.3) L/day, respectively.
No clinically significant differences in the pharmacokinetics of ravulizumab-cwvz were observed based on sex, age (10 months to 83 years), race, hepatic impairment, or any degree of renal impairment, including patients with proteinuria or receiving dialysis.
Body weight was a clinically significant covariate on the pharmacokinetics of ravulizumab-cwvz.
The safety and efficacy of ULTOMIRIS in patients with PNH was assessed in two open-label, randomized, active-controlled, non-inferiority Phase 3 studies: PNH Study 301 and PNH Study 302. Study 301 enrolled patients with PNH who were complement inhibitor naive and had active hemolysis. Study 302 enrolled patients with PNH who were clinically stable after having been treated with eculizumab for at least the past 6 months.
In both studies, ULTOMIRIS was dosed intravenously in accordance with the weight-based dosing described in Section 2.2 (4 infusions of ULTOMIRIS over 26 weeks) above. Eculizumab was administered on Days 1, 8, 15, and 22, followed by maintenance treatment with 900 mg of eculizumab on Day 29 and every 2 weeks (q2w) thereafter for a total of 26 weeks of treatment, according to the approved dosing regimen of eculizumab which was the standard-of-care for PNH at the time of studies.
Patients were vaccinated against meningococcal infection prior to or at the time of initiating treatment with ULTOMIRIS or eculizumab, or received prophylactic treatment with appropriate antibiotics until 2 weeks after vaccination. Prophylactic treatment with appropriate antibiotics beyond 2 weeks after vaccination was at the discretion of the provider.
The Complement-Inhibitor Naive Study [ALXN1210-PNH-301; NCT02946463] was a 26-week, multicenter, open-label, randomized, active-controlled, non-inferiority Phase 3 study conducted in 246 patients naive to complement inhibitor treatment prior to study entry.
Patients with PNH with flow cytometric confirmation of at least 5% PNH cells were randomized 1:1 to either ULTOMIRIS or eculizumab. The mean total PNH granulocyte clone size was 85%, the mean total PNH monocyte clone size was 88%, and the mean total PNH RBC clone size was 39%. Ninety-eight percent of patients had a documented PNH-associated condition diagnosed prior to enrollment on the trial: anemia (85%), hemoglobinuria (63%), history of aplastic anemia (32%), history of renal failure (12%), myelodysplastic syndrome (5%), pregnancy complications (3%), and other (16%). Major baseline characteristics were balanced between treatment groups.
Table 11: Baseline Characteristics in the
Complement-Inhibitor Naive Study
| Parameter | Statistics | ULTOMIRIS (N=125) |
Eculizumab (N=121) |
| Age (years) at first infusion in study | Mean (SD) Min, max | 44.8 (15.2) 18, 83 | 46.2 (16.2) 18, 86 |
| Sex | |||
| Male | n (%) | 65 (52.0) | 69 (57.0) |
| Race | n (%) | ||
| Asian | 72 (57.6) | 57 (47.1) | |
| White | 43 (34.4) | 51 (42.1) | |
| Black or African American | 2 ( 1.6) | 4 ( 3.3) | |
| American Indian or Alaska Native | 1 ( 0.8) | 1 ( 0.8) | |
| Other | 4 ( 3.2) | 4 ( 3.3) | |
| Not reported | 3 ( 2.4) | 4 ( 3.3) | |
| Median | 1513.5 | 1445.0 | |
| Pre-treatment LDH levels (U/L) | Min, max | (378.0, 3759.5) | (423.5, 3139.5) |
| Units of pRBC/whole blood | Median | 6.0 | 6.0 |
| transfused within 12 months prior to first dose | Min, max | (1, 44) | (1, 32) |
| Antithrombotic agents used within 28 days prior to first dose | n (%) | 22 (17.6) | 22 (18.2) |
| Patients with a history of MAVEa | n (%) | 17 (13.6) | 25 (20.7) |
| Patients with a history of thrombosis | n (%) | 17 (13.6) | 20 (16.5) |
| Patients with concomitant anticoagulant treatment | n (%) | 23 (18.4) | 28 (23.1) |
| a MAVE = major adverse vascular event | |||
Efficacy was established based upon transfusion avoidance and hemolysis as directly measured by normalization of LDH levels. Transfusion avoidance was defined as patients who did not receive a transfusion and not meet the protocol specified guidelines for transfusion from baseline up to Day 183. Supportive efficacy data included the percent change from baseline in LDH levels, the proportion of patients with breakthrough hemolysis defined as at least one new or worsening symptom or sign of intravascular hemolysis in the presence of elevated LDH ≥ 2 x ULN, after prior LDH reduction to < 1.5 x ULN on therapy and the proportion of patients with stabilized hemoglobin.
Non-inferiority of ULTOMIRIS to eculizumab was demonstrated across endpoints in the complement inhibitor naive treatment population described in the table below.
Table 12: Efficacy Results in the Complement-Inhibitor
Naive Study
| ULTOMIRIS (N=125) |
Eculizumab (N=121) |
Statistic for Comparison | Treatment Effect (95% CI) | |
| Transfusion avoidance rate | 73.6% | 66.1% | Difference in rate | 6.8 (-4.66, 18.14) |
| LDH normalization | 53.6% | 49.4% | Odds ratio | 1.19 (0.80, 1.77) |
| LDH percent change | -76.84% | -76.02% | Difference in % change from baseline | -0.83 (-5.21, 3.56) |
| Breakthroughhemolysis | 4.0% | 10.7% | Difference in rate | -6.7 (-14.21, 0.18) |
| Hemoglobin stabilization | 68.0% | 64.5% | Difference in rate | 2.9 (-8.80, 14.64) |
| Note: LDH = lactate
dehydrogenase; CI = confidence interval For the transfusion avoidance endpoint, treatment differences (95% CIs) are based on estimated differences in percent with 95% CI. For the lactate dehydrogenase normalization endpoint, the adjusted prevalence within each treatment is displayed. |
||||
There was no observable difference in fatigue between ULTOMIRIS and eculizumab after 26 weeks of treatment compared to baseline as measured by the FACIT-fatigue instrument. Patient-reported fatigue may be an under-or over-estimation, because patients were not blinded to treatment assignment.
The study in eculizumab-experienced patients [ALXN1210-PNH-302; NCT03056040] was a 26-week, multicenter, open-label, randomized, active-controlled, non-inferiority Phase 3 study conducted in 195 patients with PNH who were clinically stable after having been treated with eculizumab for at least the past 6 months.
Patients who demonstrated clinically stable disease after being treated with eculizumab for at least the prior 6 months were randomized 1:1 to either continue eculizumab or to switch to ULTOMIRIS. The mean total PNH granulocyte clone size was 83%, the mean total PNH monocyte clone size was 86%, and the mean total PNH RBC clone size was 60%. Ninety five percent of patients had a documented PNH-associated condition diagnosed prior to enrollment on the trial: anemia (67%), hematuria or hemoglobinuria (49%), history of aplastic anemia (37%), history of renal failure (9%), myelodysplastic syndrome (5%), pregnancy complication (7%), and other (14%). Major baseline characteristics were balanced between the two treatment groups.
Table 13: Baseline Characteristics in
Eculizumab-Experienced Patients with PNH
| Parameter | Statistics | ULTOMIRIS (N=97) |
Eculizumab (N=98) |
| Age (years) at first infusion in study | Mean (SD) | 46.6 (14.41) | 48.8 (13.97) |
| Min, max | 18, 79 | 23, 77 | |
| Race | n (%) | ||
| White | 50 (51.5) | 61 (62.2) | |
| Asian | 23 (23.7) | 19 (19.4) | |
| Black or African American | 5 (5.2) | 3 (3.1) | |
| Other | 2 (2.1) | 1 (1.0) | |
| Not reported | 13 (13.4) | 13 (13.3) | |
| Unknown | 3 (3.1) | 1 (1.0) | |
| Multiple | 1 (1.0) | 0 | |
| Sex | n (%) | ||
| Male | 50 (51.5) | 48 (49.0) | |
| Median | 224 0 | 234 0 | |
| Pre-treatment LDH levels (U/L) | Min, max | 135.0, 383.5 | 100.0, 365.5 |
| Units of pRBC/whole blood transfused within 12 months prior to first dose | Median | 4.0 | 2.5 |
| Min, max | (1, 32) | (2, 15) | |
| Antithrombotic agents used within 28 days prior to first dose | n (%) | 20 (20.6) | 13 (13.3) |
| Patients with a history of MAVEa | n (%) | 28 (28.9) | 22 (22.4) |
| Patients with a history of thrombosis | n (%) | 27 (27.8) | 21 (21.4) |
| Patients with concomitant anticoagulant treatment | n (%) | 22 (22.7) | 16 (16.3) |
| a MAVE = major adverse vascular event | |||
Efficacy was established based on hemolysis as measured by LDH percent change from baseline to Day 183 and supportive efficacy data was transfusion avoidance, proportion of patients with stabilized hemoglobin, and the proportion of patients with breakthrough hemolysis through Day 183.
Non-inferiority of ULTOMIRIS to eculizumab was demonstrated across endpoints in the patients with PNH previously treated with eculizumab described in the table below.
Table 14: Efficacy Results in the
Eculizumab-Experienced Patients with PNH Eculizumab-Experienced Study
| ULTOMIRIS N = 97 |
Eculizumab N = 98 |
Statistic for Comparison | Treatment Effect (95% CI) | |
| LDH Percent change | -0.82% | 8.4% | Difference in % change from baseline | 9.2 (-0.42, 18.8) |
| Breakthrough hemolysis | 0% | 5.1% | Difference in rate | 5.1 (-8.9, 19.0) |
| Transfusion avoidance | 87.6 % | 82.7% | Difference in rate | 5.5 (-4.3, 15.7) |
| Hemoglobin stabilization | 76.3% | 75.5% | Difference in rate | 1.4 (-10.4, 13.3) |
| Note: CI = confidence interval | ||||
There was no observable difference in fatigue between ULTOMIRIS and eculizumab after 26 weeks of treatment compared to baseline as measured by the FACIT-fatigue instrument. Patient-reported fatigue may be an under-or over-estimation, because patients were not blinded to treatment assignment.
The efficacy of ULTOMIRIS in patients with aHUS was assessed in 2 open-label, single-arm studies. Study ALXN1210-aHUS-311 enrolled adult patients who displayed signs of TMA. In order to qualify for enrollment, patients were required to have a platelet count ≤150 x 109/L, evidence of hemolysis such as an elevation in serum LDH, and serum creatinine above the upper limits of normal or required dialysis.
Study ALXN1210-aHUS-312 enrolled pediatric patients who displayed signs of TMA. In order to qualify for enrollment, patients were required to have a platelet count ≤150 x 109/L, evidence of hemolysis such as an elevation in serum LDH, and serum creatinine level ≥97.5% percentile at screening or required dialysis. In both studies, enrollment criteria excluded patients presenting with TMA due to a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) deficiency, Shiga toxin Escherichia coli related hemolytic uremic syndrome (STEC-HUS) and genetic defect in cobalamin C metabolism. Patients with confirmed diagnosis of STEC-HUS after enrollment were excluded from the efficacy evaluation.
The adult study [ALXN1210-aHUS-311; NCT02949128] was conducted in patients who were naive to complement inhibitor treatment prior to study entry. The study consisted of a 26-week Initial Evaluation Period and patients were allowed to enter an extension period for up to 4.5 years.
A total of 56 patients with aHUS were evaluated for efficacy. Ninety-three percent of patients had extra-renal signs (cardiovascular, pulmonary, central nervous system, gastrointestinal, skin, skeletal muscle) or symptoms of aHUS at baseline. At baseline, 71.4% (n = 40) of patients had Stage 5 chronic kidney disease (CKD). Fourteen percent had a medical history of kidney transplant and 51.8% were on dialysis at study entry. Eight patients entered the study with evidence of TMA for > 3 days after childbirth (ie, postpartum).
Table 15 presents the demographics and baseline characteristics of the 56 adult patients enrolled in Study ALXN1210-aHUS-311 that constituted the Full Analysis Set.
Table 15: Demographics and Baseline Characteristics in
Study ALXN1210-aHUS-311
| Parameter | Statistics | ULTOMIRIS (N=56) |
| Age at time of first infusion (years) | Mean (SD) | 42.2 (14.98) |
| Min, max | 19.5, 76.6 | |
| Sex | ||
| Female | n(%) | 37 (66.1) |
| Racea | n (%) | |
| White | 29 (51.8) | |
| Asian | 15 (26.8) | |
| Unknown | 8 (14.3) | |
| Other | 4 (7.1) | |
| Platelets (109/L) blood | n | 56 |
| [normal range 130 to 400 x 109/L] | Median (min,max) | 95.25 (18, 473) |
| Hemoglobin (g/L) blood | n | 56 |
| [normal range 115 to 160 g/L (female), 130 to 175 g/L (male)l | Median (min,max) | 85.00 (60.5, 140) |
| LDH (U/L) serum | n | 56 |
| [normal range 120 to 246 U/L] | Median (min,max) | 508.00 (229.5, 3249) |
| eGFR (mL/min/1.73 m²) | n (%) | 55 |
| [normal range ≥ 60 mL/min/1.73 m²] | Mean (SD) | 15.86 (14.815) |
| Median (min,max) | 10.00 (4, 80) | |
| Note: Percentages are based on the total number of patients. a Patients can have multiple races selected. Abbreviations: eGFR = estimated glomerular filtration rate; LDH = lactate dehydrogenase; max = maximum; min = minimum. |
||
The efficacy evaluation was based on Complete TMA Response during the 26-week Initial Evaluation Period, as evidenced by normalization of hematological parameters (platelet count and LDH) and ≥ 25% improvement in serum creatinine from baseline. Patients had to meet each Complete TMA Response criteria at 2 separate assessments obtained at least 4 weeks (28 days) apart, and any measurement in between.
Complete TMA Response was observed in 30 of the 56 patients (54%) during the 26-week Initial Evaluation Period as shown in Table 16.
Table 16: Efficacy Results in aHUS during the 26-Week
Initial Evaluation Period (ALXN1210-aHUS-311)
| Total | Responder | ||
| n | Proportion (95% CI)a | ||
| Complete TMA Response | 56 | 30 | 0.54 (0.40, 0.67) |
| Components of Complete TMA Response Platelet count normalization | 56 | 47 | 0.84 (0.72, 0.92) |
| LDH normalization | 56 | 43 | 0.77 (0.64, 0.87) |
| ≥25% improvement in serum creatinine from baseline | 56 | 33 | 0.59 (0.45, 0.72) |
| Hematologic normalization | 56 | 41 | 0.73 (0.60, 0.84) |
| a 95% CIs for the proportion were based on
exact confidence limits using the Clopper-Pearson method. Abbreviations: CI = confidence interval; LDH = lactate dehydrogenase; TMA = thrombotic microangiopathy. |
|||
One additional patient had a Complete TMA Response that was confirmed after the 26-week Initial Evaluation Period. Complete TMA Response was achieved at a median time of 86 days (range: 7 to 169 days). The median duration of Complete TMA Response was 7.97 months (range: 2.52 to 16.69 months). All responses were maintained through all available follow-up.
Other endpoints included platelet count change from baseline, dialysis requirement, and renal function as evaluated by estimated glomerular filtration rate (eGFR).
An increase in mean platelet count was observed after commencement of ULTOMIRIS, increasing from 118.52 x 109/L at baseline to 240.34 x109/L at Day 8 and remaining above 227 x 109/L at all subsequent visits in the Initial Evaluation Period (26 weeks).
Renal function, as measured by eGFR, was improved or maintained during ULTOMIRIS therapy. The mean eGFR (+/- SD) increased from 15.86 (14.82) at baseline to 51.83 (39.16) by 26 weeks. In patients with Complete TMA Response, renal function continued to improve after the Complete TMA Response was achieved.
Seventeen of the 29 patients (59%) who required dialysis at study entry discontinued dialysis by the end of the available follow-up and 6 of 27 (22%) patients were off dialysis at baseline were on dialysis at last available follow-up.
The Pediatric Study [ALXN1210-aHUS-312; NCT03131219] is a 26-week ongoing, multicenter, single-arm, study conducted in 16 pediatric patients.
A total of 14 eculizumab-naive patients with documented diagnosis of aHUS were enrolled and included in this interim analysis. The median age at the time of first infusion was 5.2 years (range 0.9, 17.3 years). The overall mean weight at Baseline was 19.8 kg; half of the patients were in the baseline weight category ≥ 10 to < 20 kg. The majority of patients (71%) had pretreatment extra-renal signs (cardiovascular, pulmonary, central nervous system, gastrointestinal, skin, skeletal muscle) or symptoms of aHUS at baseline.
At baseline, 35.7% (n = 5) of patients had a CKD Stage 5. Seven percent had history of prior kidney transplant and 35.7% were on dialysis at study entry.
Table 17 presents the baseline characteristics of the pediatric patients enrolled in Study ALXN1210-aHUS-312.
Table 17: Demographics and Baseline Characteristics in Study ALXN1210-aHUS-312
| Parameter | Statistics | ULTOMIRIS (N = 14) |
| Age at time of first infusion (years) category | n (%) | |
| Birth to < 2 years | 2 (14.3) | |
| 2 to < 6 years | 7 (50.0) | |
| 6 to < 12 years | 4 (28.6) | |
| 12 to < 18 years | 1 (7.1) | |
| Sex | n (%) | |
| Female | 9 (64.3) | |
| Racea | n (%) | |
| White | 7 (50.0) | |
| Asian | 4 (28.6) | |
| Black or African American | 2 (14.3) | |
| American Indian or Alaskan Native | 1 (7.1) | |
| Unknown | 1 (7.1) | |
| Platelets (109/L) blood [normal range 229 to | ||
| 533 x 109/L] | Median (min, max) | 64.00 (14, 125) |
| Hemoglobin (g/L) blood [normal range 107 to 131 | ||
| g/Ll | Median (min, max) | 74.25 (32, 106) |
| LDH (U/L) serum [normal range 165 to 395 U/L] | Median (min, max) | 2077.00 (772, 4985) |
| eGFR (mL/min/1.73 m²) [normal range | Mean (SD) | 28.4 (23.11) |
| ≥ 60 mL/min/1.73 m²] | Median (min, max) | 22.0 (10, 84) |
| Note: Percentages are based on the total number of
patients. a Patients can have multiple races selected. Abbreviations: eGFR = estimated glomerular filtration rate; LDH = lactate dehydrogenase; max = maximum; min = minimum. |
||
Efficacy evaluation was based upon Complete TMA Response during the 26-week Initial Evaluation Period, as evidenced by normalization of hematological parameters (platelet count and LDH) and ≥ 25% improvement in serum creatinine from baseline. Patients had to meet all Complete TMA Response criteria at 2 separate assessments obtained at least 4 weeks (28 days) apart, and any measurement in between.
Complete TMA Response was observed in 10 of the 14 patients (71%) during the 26-week Initial Evaluation Period as shown in Table 18.
Table 18: Efficacy Results in aHUS during the 26-Week
Initial Evaluation Period (ALXN1210-aHUS-312)
| Total | Responder | ||
| n | Proportion (95% CI)a | ||
| Complete TMA Response | 14 | 10 | 0.71 (0.42, 0.92) |
| Components of Complete TMA Response | |||
| Platelet count normalization | 14 | 13 | 0.93 (0.66, 0.99) |
| LDH normalization | 14 | 12 | 0.86 (0.57, 0.98) |
| ≥25% improvement in serum creatinine from baseline | 14 | 11 | 0.79 (0.49, 0.95) |
| Hematologic normalization | 14 | 12 | 0.86 (0.57, 0.98) |
| Note: 1 patient withdrew from study after receiving 2
doses of ravulizumab. a 95% CIs for the proportion were based on on exact confidence limits using the Clopper-Pearson method. Abbreviations: CI = confidence interval; LDH = lactate dehydrogenase; TMA = thrombotic microangiopathy. |
|||
Complete TMA Response during the Initial Evaluation Period was achieved at a median time of 30 days (range:15 to 88 days). The median duration of Complete TMA Response was 5.08 months (range: 3.08 to 5.54 months). All responses were maintained through all available follow-up.
Other endpoints included platelet count change from baseline, dialysis requirement, and renal function as evaluated by eGFR.
An increase in mean platelet count was observed after commencement of ULTOMIRIS, increasing from 60.50 x 109/L at baseline to 296.67 x 109/L at Day 8 and remained above 296 x 109/L at all subsequent visits in the Initial Evaluation Period (26 weeks). The mean eGFR (+/- SD) increased from 28.4 (23.11) at baseline to 108.0 (63.21) by 26 weeks.
Four of the 5 patients who required dialysis at study entry were able to discontinue dialysis after the first month in study and for the duration of ULTOMIRIS treatment. No patient started dialysis during the study.
ULTOMIRIS®
(ul-toe-meer-is)
(ravulizumab-cwvz) injection, for intravenous use
What is the most important information I should know about ULTOMIRIS?
ULTOMIRIS is a medicine that affects your immune system. ULTOMIRIS can lower the ability of your immune system to fight infections.
Call your doctor or get emergency medical care right away if you get any of these signs and symptoms of a meningococcal infection:
Your doctor will give you a Patient Safety Card about the risk of meningococcal infection. Carry it with you at all times during treatment and for 8 months after your last ULTOMIRIS dose. Your risk of meningococcal infection may continue for several months after your last dose of ULTOMIRIS. It is important to show this card to any doctor or nurse who treats you. This will help them diagnose and treat you quickly.
ULTOMIRIS is only available through a program called the ULTOMIRIS REMS. Before you can receive ULTOMIRIS, your doctor must:
ULTOMIRIS may also increase the risk of other types of serious infections.
Call your doctor right away if you have any new signs or symptoms of infection.
What is ULTOMIRIS?
ULTOMIRIS is a prescription medicine called a monoclonal antibody. ULTOMIRIS is used to treat:
ULTOMIRIS is not used in treating people with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS).
It is not known if ULTOMIRIS is safe and effective in children with PNH.
It is not known if ULTOMIRIS is safe and effective in children younger than 1 month of age.
Who should not receive ULTOMIRIS?
Do not receive ULTOMIRIS if you:
Before you receive ULTOMIRIS, tell your doctor about all of your medical conditions, including if you:
Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. ULTOMIRIS and other medicines can affect each other causing side effects.
Know the medicines you take and the vaccines you receive. Keep a list of them to show your doctor and pharmacist when you get a new medicine.
How should I receive ULTOMIRIS?
If you are an adult with PNH or aHUS, you will usually receive:
Children 1 month of age and older with aHUS will usually receive:
Your doctor will decide how long you need to take ULTOMIRIS for your aHUS.
Symptoms or problems that can happen due to red blood cell breakdown include:
If you miss an ULTOMIRIS infusion, call your doctor right away.
What are the possible side effects of ULTOMIRIS?
ULTOMIRIS can cause serious side effects including:
Your doctor will treat your symptoms as needed.
The most common side effects of ULTOMIRIS in people treated for PNH are upper respiratory infection and headache.
The most common side effects of ULTOMIRIS in people with aHUS are:
Tell your doctor about any side effect that bothers you or that does not go away.
These are not all the possible side effects of ULTOMIRIS. For more information, ask your doctor or pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
General information about the safe and effective use of ULTOMIRIS.
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. You can ask your pharmacist or doctor for information about ULTOMIRIS that is written for health professionals.
What are the ingredients in ULTOMIRIS?
Active ingredient: ravulizumab-cwvz
Inactive ingredients: polysorbate 80 (vegetable origin), sodium chloride, sodium phosphate dibasic, sodium phosphate monobasic, and Water for Injection
This Medication Guide has been approved by the U.S. Food and Drug Administration.
